Search Results

APRINOIA Therapeutics today announced that on May 8, 2024, the U.S. Food and Drug Administration (FDA) granted Fast Track Designation (FTD) to APN-1607 (florzolotau), a Positron Emission Tomography (PET) tracer for imaging tau protein in patients with suspected progressive supranuclear palsy (PSP).

APRINOIA Therapeutics (“APRINOIA” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics and precision diagnostics for the treatment of neurodegenerative diseases, headquartered in Cambridge, MA, is pleased to announce the strategic investment by the Alzheimer’s Drug Discovery Foundation (ADDF) of approximately $4.4M.

APRINOIA Therapeutics announced a mutual termination of its previously announced business combination agreement with Ross Acquisition Corp II, a special purpose acquisition company.

APRINOIA Therapeutics, a global clinical-stage biopharmaceutical company developing novel therapeutics and precision diagnostics for the treatment of neurodegenerative diseases such as Alzheimer’s Disease, Parkinson’s Disease, and certain rare dementia and movement disorders, announced that its Board of Directors has appointed Mark S. Shearman, Ph.D. as Chief Executive Officer.

APRINOIA Therapeutics Inc. and Progressive Supranuclear Palsy (“PSP”), and Ross Acquisition Corp II today announced that they have entered into a definitive agreement (the “Business Combination Agreement”) for a business combination (the “Business Combination”).

APRINOIA Therapeutics announces that the U.S. Food and Drug Administration has granted a may proceed authorization for its novel therapeutic anti-tau monoclonal antibody, APNmAb005, allowing the company to test and evaluate its safety in healthy subjects in a phase 1 single ascending dose study.

APRINOIA Therapeutics Inc. today announced that they had executed a worldwide non-exclusive licensing agreement for Biogen Inc. (Nasdaq: BIIB) to access APRINOIA’s positron emission tomography (PET) imaging tracer, 18F-APN-1607, for neurodegenerative diseases

We are in an unprecedented time in neurotherapeutics. Medicines that address the causative disease biology underlying central nervous system

Seaport Therapeutics today announced it has expanded its executive team with the appointment of Antony Loebel, M.D., as Chief Medical Officer and President of Clinical Development, and Lana Gladstein, J.D., as General Counsel.

APRINOIA Therapeutics announced that China National Medical Products Administration had approved to initiate Phase 3 clinical trial to evaluate APRINOIA’s positron emission tomography imaging tracer, 18F-APN-1607, targeting abnormal tau protein aggregates in brains of patients of cognitive impairment.